Introduction
Anemia is a nearly universal complication of end-stage kidney disease (ESKD). Management typically involves a combination of Erythropoiesis-Stimulating Agents (ESAs) and iron supplementation. In clinical practice, treatment decisions are guided by two primary blood markers: serum ferritin, which reflects total body iron stores, and transferrin saturation (TSAT), which indicates the availability of iron for red blood cell production.
However, ferritin is a complex biomarker. While it serves as an iron storage protein, it is also an acute-phase reactant that rises significantly during periods of inflammation or infection. This dual nature creates a significant clinical dilemma, particularly for First Nations Australians in the Northern Territory, who often exhibit high ferritin levels (>700 µg/L) alongside low TSAT (<40%).
The Clinical Dilemma: The Ferritin Paradox
Current international guidelines generally advise withholding intravenous (IV) iron when ferritin levels exceed 500 or 800 µg/L to avoid the risks of iron overload, which can lead to organ damage and increased susceptibility to infections. However, in populations with high baseline inflammatory markers, these elevated ferritin levels may not indicate "too much iron." Instead, patients may experience "functional iron deficiency," where iron is sequestered and unavailable for erythropoiesis.
Withholding iron in these cases may leave anemia undertreated, necessitating higher, potentially more toxic doses of ESAs. Conversely, administering iron might risk toxicity or "feed" bacterial infections. There is currently a lack of high-quality evidence to guide the safe and effective use of iron in patients with this specific profile of hyperferritinemia and low TSAT.
The INFERR Study Design
The INFERR study (INtravenous Iron Polymaltose for First Nations Patients With High FERRitin Levels On Haemodialysis) is a prospective, open-label, blinded endpoint randomized controlled trial (PROBE design) designed to address this uncertainty.
Participants and Intervention
The study aims to recruit 576 First Nations Australians on maintenance hemodialysis from seven renal units across the Northern Territory who meet the criteria of high ferritin (700–2000 µg/L) and low TSAT (<40%). Participants are randomized 1:1 into two groups:
- Arm A (Intervention): Patients receive 400mg of intravenous iron polymaltose once monthly (administered as 200mg during two consecutive dialysis sessions).
- Arm B (Control/Standard Care): IV iron is withheld unless ferritin levels drop below 700 µg/L or if treatment is clinically indicated as rescue therapy.
Blinding and Data Management
While the trial is open-label—meaning patients and clinical staff are aware of the treatment assignment—the study employs a blinded endpoint design. The primary outcomes are adjudicated by an independent committee of nephrologists who remain unaware of the treatment allocation, thereby minimizing potential bias. Data is captured via the Redcap (Research Electronic Data Capture) system and tracked through hospital records and the Australian New Zealand Clinical Trials Registry (ANZCTR).
Advanced Diagnostics
To move beyond the limitations of blood biomarkers, a subset of participants will undergo MRI FerriScan. This non-invasive imaging technique is considered the "gold standard" for measuring liver iron concentration, providing a definitive assessment of whether high ferritin levels truly correlate with iron overload in this population.
Objectives and Outcomes
The INFERR trial is specifically powered to evaluate "hard" clinical endpoints rather than just surrogate laboratory markers.
- Primary Outcome: The difference between the two study arms in the risk of a composite endpoint: all-cause death or hospitalization with a principal diagnosis of infection. The study is designed with 80% power to detect a 30% reduction in this composite outcome over a 36-month follow-up period.
- Secondary Outcomes: These include changes in hemoglobin levels, total ESA requirements, and a comprehensive economic analysis to determine the cost-effectiveness of the intervention.
Significance and Future Impact
The results of the INFERR trial will provide much-needed evidence to resolve the uncertainty surrounding iron therapy in patients with chronic inflammation. By focusing on First Nations Australians, the study addresses a significant health equity gap, as this population is frequently excluded from large-scale global clinical trials.
Ultimately, the findings will support the development of evidence-based, culturally and clinically relevant guidelines for iron management. Furthermore, the study offers a unique opportunity to explore the underlying causes of hyperferritinemia in populations with high infectious and cardiovascular disease burdens, potentially serving as a model for managing similar cohorts worldwide.
Summary updated